Crenolanib - CP-868596 | ARO-002 | Plarotinib

Based on 173 reference(s) in Google Scholar 8 10 173

Axon 3969

CAS [670220-88-9]

MF C26H29N5O2
MW 443.54

  • Purity: 99%
  • Soluble in DMSO



Crenolanib is an orally bioavailable, selective small molecule inhibitor of the Platelet-derived growth factor receptor (PDGFR) tyrosine kinase, inhibiting both purified PDGFRα and PDGFRβ with IC50s of 0.9 nM and 1.8 nM, respectively. It is also a type I pan-FLT3 inhibitor, highly selective over the closely related protein tyrosine kinase KIT, capable of inhibiting both FLT3/ITD and resistance-conferring FLT3/D835 mutants in vivo. It is considered to be an important next-generation FLT3 inhibitor.

KEYWORDS: Crenolanib | Supplier | PDGFRα |  PDGFRβ and FLT3 inhibitor | CP-868596 | ARO-002 | Plarotinib | CP868596 | CP 868596 | ARO002 | ARO 002 | CT-CREN | CAS [670220-88-9] | PDGF | PDGFR | FLT3 | Inhibitor | Receptors

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...